Advanced search
Start date

Cancer Theranostics Innovation Center (CancerThera)

Grant number: 21/10265-8
Support Opportunities:Research Grants - Research, Innovation and Dissemination Centers - RIDC
Duration: May 01, 2023 - April 30, 2028
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Carmino Antonio de Souza
Grantee:Carmino Antonio de Souza
Host Institution: Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
Pesquisadores principais:
Carmen Silvia Passos Lima ; Celso Darío Ramos ; ELBA CRISTINA SÁ DE CAMARGO ETCHEBEHERE ; José Barreto Campello Carvalheira ; Pedro Paulo Corbi ; Victor Marcelo Deflon
Associated researchers:ALLAN DE OLIVEIRA SANTOS ; Ana Lúcia Tasca Gois Ruiz ; Bárbara Juarez Amorim ; Bruno Kosa Lino Duarte ; Daniel Massaro Onusic ; Denise Engelbrecht Zantut Wittmann ; Edna Marina de Souza ; Fabiano Reis ; Fernando Rodrigues Goulart Bergamini ; Fernando Vieira Pericole de Souza ; Gislaine Oliveira Duarte ; Guilherme Brasil Duffles Amarante ; Gustavo Jacob Lourenço ; João Ernesto de Carvalho ; José Vassallo ; Jun Takahashi ; Katia Borgia Barbosa Pagnano ; Leonardo Lima Fuscaldi ; Ligia Traldi Macedo ; Luciana Malavolta Quaglio ; Ludmila Santiago Almeida ; Maria Carolina Santos Mendes ; Maria Cristina Cintra Gomes Marcondes ; Maria Emilia Seren Takahashi ; Mariana da Cunha Lopes de Lima ; Pedro Ivo da Silva Maia ; Samuel de Souza Medina ; Sergio Querino Brunetto ; Sergio San Juan Dertkigil ; Sibila Roberta Marques Grallert ; Thiago Ferreira de Souza ; Vânia Pereira de Castro Rodrigues
Associated scholarship(s):23/09854-4 - Evaluation of new silver complexes as innovative therapeutic strategies for treatment of Skin Squamous Cell Carcinoma, BP.DR


Cancer is a major public health problem worldwide and ranks among the leading causes of death. Identifying new agents for the diagnosis and treatment of patients with cancer is highly desirable. For many centuries, metals have been used empirically to treat various diseases. Nowadays, metals and their compounds - stable or radioactive - are rationally applied in both the diagnosis and treatment of neoplasms. A new type of cancer approach has gained worldwide prominence, the theranostic approach, a deriving term from "therapy" and "diagnosis". The overall theranostics concept involves identifying an active molecule related to a treatable target and subsequently radiolabeling the molecule for diagnosis (gamma or positron emitters) and therapeutic purposes (alpha or beta emitters). By reuniting researchers from a wide range of fields of expertise including such as Clinical Oncology, Onco-Hematology, Chemistry, Nuclear Medicine, Pharmacy, Statistics, Biology, and Physics, the effort aims to produce a Cancer Theranostics Innovation Center (CancerThera). CancerThera's goal is to develop an internationally competitive research center with qualified human resources for the creation and manipulation of pharmaceuticals and radiopharmaceuticals ((radio)pharmaceuticals) for the diagnosis and treatment of cancer in a theranostics approach. CancerThera will be divided into two interconnected teams - Basic Research and Clinical Research - which will develop converging projects. CancerThera Basic Research: Bioactive molecules will serve to synthesize new Metallo(radio)pharmaceuticals with potential action in diagnosis and blockage of tumor cell replications. Compounds and chelators will be conjugated with various tumor microenvironment-related peptides. The compounds will be radiolabeled with the pair gallium-68 and lutetium-177, which, respectively, allow the diagnosis and treatment of neoplasms, in addition to other radioisotopes. The biodistribution and/or antitumor action of the compounds will be evaluated in various preclinical studies. Investigations will include gamma counter analysis, micro-PET/SPECT/CT imaging, antiproliferative activity and cell death assays in tumor cell lines, and conventional evaluation. Further, inflammation/gene expression assays of toxicity and efficacy will be performed in animal tumor models. CancerThera Clinical Research: Possible new uses for already known molecules will be studied. The existing radiopharmacy at the host institution will be further set up and developed by the International Atomic Energy Agency project in force. The current radiopharmacy infrastructure will label various diagnostic oncology-based radioisotopes for possible cancer treatments. Investigations will be conducted on various cancer types (such as multiple myeloma, indolent lymphomas, colorectal and gastric cancers, glioblastoma multiforme, head, and neck cutaneous squamous cell carcinoma, Ph1-negative chronic myeloproliferative diseases, etc.). Genetic analysis of the radioactive-avid lesions will be performed. Continuous interaction between the CancerThera Basic and Clinical Research teams will take place in an unprecedented model in the country in this area. Thus, the radiopharmaceuticals successfully produced in Basic Research will be used in phase 1 and, eventually, phase 2 clinical studies. Likewise, new applications of known drugs will have their radiolabeling monitored by the Basic Research investigators. To ensure appropriation of the results of CancerThera by the society, different players from several institutions will be interconnected including investigators, scholars, research organizations, national and international funding agencies, micro-enterprises and large business corporations, governments (state and municipal), press, and ultimately the Brazilian society. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
NUNES, JULIA HELENA BORMIO; NAKAHATA, DOUGLAS HIDEKI; CORBI, PEDRO PAULO; PAIVA, RAPHAEL ENOQUE FERRAZ DE. Beyond silver sulfadiazine: A dive into more than 50 years of research and development on metal complexes of sulfonamides in medicinal inorganic chemistry. Coordination Chemistry Reviews, v. 490, p. 45-pg., . (21/10265-8, 21/08717-8)
SILVA, AMANDA A.; FRAJACOMO, SILMARA C. L.; CRUZ, ALLEFE B.; BUGLIO, KAIO EDUARDO; AFFONSO, DANIELE DAIANE; PORTES, MARCELO CECCONI; RUIZ, ANA LUCIA T. G.; DE CARVALHO, JOAO ERNESTO; LUSTRI, WILTON R.; PEREIRA, DOUGLAS H.; et al. Copper(II) and Platinum(II) Naproxenates: Insights on Synthesis, Characterization and Evaluation of Their Antiproliferative Activities. INORGANICS, v. 11, n. 8, p. 21-pg., . (13/07937-8, 18/12062-4, 21/07458-9, 21/10265-8, 11/01114-4, 14/23950-7, 21/08717-8)

Please report errors in scientific publications list by writing to: